Systemic administration of a P2X7R antagonist to tumor-bearing WT mice reduces tumor growth and upsets the immune infiltrate causing on one hand an increase in CD4+ and Teff cells, and on the other a down-modulation of both NTPDase1/CD39 and NT5E/CD73 expressed by CD8+ Treg cells (De Marchi et al., 2019). Here, ENTPD1 is linked to neoplasm.